Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388(10061):2796–2810. doi:10.1016/S0140-6736(16)30512-8
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Agarwal N, et al. NCCN guidelines insights: bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018;16(9):1041–1053. doi:10.6004/jnccn.2018.0072
   PubMed Web of Science ®Google Scholar
• Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–1029. doi:10.1016/j.juro.2016.06.049
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–653. doi:10.1016/j.eururo.2013.06.003
   PubMed Web of Science ®Google Scholar
• Richards KA, Smith ND, Steinberg GD. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. J Urol. 2014;191(6):1655–1664. doi:10.1016/j.juro.2014.01.087
   PubMed Web of Science ®Google Scholar
• Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic differences between” Primary” and” Secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy. Eur Urol. 2019;75(2):231–239. doi:10.1016/j.eururo.2018.09.002
   PubMed Web of Science ®Google Scholar
• Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790–797. doi:10.1016/j.eururo.2006.01.017
   PubMed Web of Science ®Google Scholar
• Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004;45(3):292–296. doi:10.1016/j.eururo.2003.10.006
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970. doi:10.1016/S0022-5347(05)64273-5
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–183. doi:10.1016/S0022-5347(17)58737-6
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi:10.1016/j.eururo.2019.08.016
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–6; discussion 6–7. doi:10.1016/j.urology.2003.11.049
   Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–95. doi:10.1016/S0022-5347(05)64043-8
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–1129. doi:10.1016/S0022-5347(05)67707-5
   PubMed Web of Science ®Google Scholar
• Davies BJ, Hwang TJ, Kesselheim AS. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer. N Engl J Med. 2017;376(15):1401–1403. doi:10.1056/NEJMp1615697
   PubMed Web of Science ®Google Scholar
• Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi:10.1016/j.eururo.2012.10.039
   PubMed Web of Science ®Google Scholar
• Herr HW, Dalbagni G, Donat SM. Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol. 2011;60(1):32–36. doi:10.1016/j.eururo.2011.03.051
   PubMed Web of Science ®Google Scholar
• Martínez-Piñeiro L, Portillo JA, Fernández JM, et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol. 2015;68(2):256–262. doi:10.1016/j.eururo.2015.02.040
   PubMed Web of Science ®Google Scholar
• Grimm MO, van der Heijden AG, Colombel M, et al. Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III clinical trial” NIMBUS”. Eur Urol. 2020;78(5):690–698. doi:10.1016/j.eururo.2020.04.066
   PubMed Web of Science ®Google Scholar
• Malmström PU. Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol. 2003;47(2):109–126. doi:10.1016/S1040-8428(03)00075-1
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69(2):231–244. doi:10.1016/j.eururo.2015.05.050
   PubMed Web of Science ®Google Scholar
• Messing EM, Tangen CM, Lerner SP, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA. 2018;319(18):1880–1888. doi:10.1001/jama.2018.4657
   PubMed Web of Science ®Google Scholar
• Chou R, Selph S, Buckley DI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol. 2017;197(5):1189–1199. doi:10.1016/j.juro.2016.12.090
   PubMed Web of Science ®Google Scholar
• Ourfali S, Ohannessian R, Fassi-Fehri H, Pages A, Badet L, Colombel M. Recurrence rate and cost consequence of the shortage of bacillus Calmette-Guerin Connaught strain for bladder cancer patients. Eur Urol Focus. 2021;7(1):111–116. doi:10.1016/j.euf.2019.04.002
   PubMedGoogle Scholar